XBI vs. SMMT

In the year-to-date period, XBI achieves a -13.34% return, which is significantly lower than SMMT's 38.13% return. Over the past 10 years, XBI has underperformed SMMT with an annualized return of 0.54%, while SMMT has yielded a comparatively higher 8.78% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and Summit Therapeutics Inc. (SMMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current XBI Sharpe Ratio is -0.45, which is lower than the SMMT Sharpe Ratio of 1.34. The chart below compares the historical Sharpe Ratios of XBI and SMMT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

XBI's dividend yield for the trailing twelve months is around 0.18%, while SMMT has not paid dividends to shareholders.

The maximum XBI drawdown since its inception was -63.89%, smaller than the maximum SMMT drawdown of -95.75%. Use the drawdown chart below to compare losses from any high point for XBI and SMMT. For additional features, visit the drawdowns tool.

The current volatility for SPDR S&P Biotech ETF (XBI) is 13.05%, while Summit Therapeutics Inc. (SMMT) has a volatility of 60.73%. This indicates that XBI experiences smaller price fluctuations and is considered to be less risky than SMMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.